Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2

    Thumbnail
    Citations
    Scopus
    Web of Science
    Altmetric
    4
    1
    Author
    Klemm, T; Ebert, G; Calleja, DJ; Allison, CC; Richardson, LW; Bernardini, JP; Lu, BGC; Kuchel, NW; Grohmann, C; Shibata, Y; ...
    Date
    2020-08-26
    Source Title
    The EMBO Journal
    Publisher
    WILEY
    University of Melbourne Author/s
    Lessene, Guillaume; Allison, Cody; Ebert, Gregor; Lowes, Kym; Dewson, Grant; Pellegrini, Marc; Au, Amanda; Feltham, Rebecca; Doerflinger, Marcel; Lechtenberg, Bernhard; ...
    Affiliation
    Medical Biology (W.E.H.I.)
    Metadata
    Show full item record
    Document Type
    Journal Article
    Citations
    Klemm, T., Ebert, G., Calleja, D. J., Allison, C. C., Richardson, L. W., Bernardini, J. P., Lu, B. G. C., Kuchel, N. W., Grohmann, C., Shibata, Y., Gan, Z. Y., Cooney, J. P., Doerflinger, M., Au, A. E., Blackmore, T. R., van der Heden van Noort, G. J., Geurink, P. P., Ovaa, H., Newman, J. ,... Komander, D. (2020). Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2. EMBO JOURNAL, 39 (18), https://doi.org/10.15252/embj.2020106275.
    Access Status
    Access this item via the Open Access location
    URI
    http://hdl.handle.net/11343/254545
    DOI
    10.15252/embj.2020106275
    Open Access URL
    https://europepmc.org/articles/PMC7461020?pdf=render
    Abstract
    The SARS-CoV-2 coronavirus encodes an essential papain-like protease domain as part of its non-structural protein (nsp)-3, namely SARS2 PLpro, that cleaves the viral polyprotein, but also removes ubiquitin-like ISG15 protein modifications as well as, with lower activity, Lys48-linked polyubiquitin. Structures of PLpro bound to ubiquitin and ISG15 reveal that the S1 ubiquitin-binding site is responsible for high ISG15 activity, while the S2 binding site provides Lys48 chain specificity and cleavage efficiency. To identify PLpro inhibitors in a repurposing approach, screening of 3,727 unique approved drugs and clinical compounds against SARS2 PLpro identified no compounds that inhibited PLpro consistently or that could be validated in counterscreens. More promisingly, non-covalent small molecule SARS PLpro inhibitors also target SARS2 PLpro, prevent self-processing of nsp3 in cells and display high potency and excellent antiviral activity in a SARS-CoV-2 infection model.

    Export Reference in RIS Format     

    Collections